Charles River Laboratories supplies research models, laboratory services and outsourced drug discovery and safety assessment to pharmaceutical, biotech and academic clients. Its offerings range from animal models and genetically engineered research tools to preclinical toxicology, pathology and manufacturing support for biologics. The company is a key outsourced partner in the early stages of bringing therapies from lab to clinic.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 984.2 | — | 25.5 | — |
| Q2 2025 | 1,032.1 | — | 52.3 | — |
| Q3 2025 | 1,004.9 | — | 54.4 | — |
| Q4 2025 | 994.2 | — | -276.6 | — |
| Q1 2026 | 995.8 | 1.2% | -14.8 | -158.3% |
| Q2 2026 | 1,004.1 | -2.7% | -1.5 | -102.8% |
All markets — KeepWinning global stock screener
Other companies on NYSE: Pinnacle Financial Partners, Inc. (PNFP), DICK'S Sporting Goods, Inc. (DKS), TransUnion (TRU), Wayfair Inc. (W), Weyerhaeuser Company (WY), Tencent Music Entertainment Group (TME)